Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Inclusion Criteria: 1. Able and willing to provide a written informed consent; 2. Male or female subjects, 18-65 years of age at the time of signing informed consent; 3. At screening visit, 28.0 ≤BMI≤ 40.0 kg/m2; 4. Diet and exercise control for at least 3 months before screening visit, and less than 5 kg self-reported change within the last 3 months. Exclusion Criteria: 1. Presence of - clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit; 2. Uncontrollable hypertension; 3. PHQ-9 score ≥15; 4. Medical history or illness that affects your weight; 5. History of diabetes; 6. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening; 7. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening; 8. Any organ-system malignancies developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix; 9. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness; 10. History of alcohol and/or substance abuse or drug abuse within 1 year prior to screening; 11. Use of any medication or treatment that may have caused significant weight change within 3 months; 12. History of bariatric surgery; 13. Known or suspected hypersensitivity to trial product(s) or related products; 14. Participation in other clinical trials for any weight-loss indication within 3 months prior to screening, or participation in other clinical trials for any drug or medical device within 1 month prior to screening; 15. history of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening; 16. Surgery is planned during the trial; 17. Mentally incapacitated or speech-impaired; 18. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method; 19. Researchers and relevant staff of the research Centre or other people directly involved in the implementation of the programme, and their immediate family members.